These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 19374962

  • 1. Remission in schizophrenia: analysis in a naturalistic setting.
    Eberhard J, Levander S, Lindström E.
    Compr Psychiatry; 2009; 50(3):200-8. PubMed ID: 19374962
    [Abstract] [Full Text] [Related]

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 3. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP, Bossie CA, Lachaux B, Bouhours P, Zhu Y, Lasser R, Gharabawi GM.
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [Abstract] [Full Text] [Related]

  • 4. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [Abstract] [Full Text] [Related]

  • 5. Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission.
    Alenius M, Hammarlund-Udenaes M, Hartvig P, Sundquist S, Lindström L.
    Compr Psychiatry; 2009 Dec; 50(5):453-62. PubMed ID: 19683616
    [Abstract] [Full Text] [Related]

  • 6. Psychotic symptoms in patients with bipolar mania.
    Canuso CM, Bossie CA, Zhu Y, Youssef E, Dunner DL.
    J Affect Disord; 2008 Dec; 111(2-3):164-9. PubMed ID: 18378001
    [Abstract] [Full Text] [Related]

  • 7. Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine.
    Wobrock T, Köhler J, Klein P, Falkai P.
    Acta Psychiatr Scand; 2009 Aug; 120(2):120-8. PubMed ID: 19392812
    [Abstract] [Full Text] [Related]

  • 8. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.
    Takahashi T, Wood SJ, Yung AR, Soulsby B, McGorry PD, Suzuki M, Kawasaki Y, Phillips LJ, Velakoulis D, Pantelis C.
    Arch Gen Psychiatry; 2009 Apr; 66(4):366-76. PubMed ID: 19349306
    [Abstract] [Full Text] [Related]

  • 9. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [Abstract] [Full Text] [Related]

  • 10. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, Risperidone Long-Acting Trial Investigators (R-LAI).
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [Abstract] [Full Text] [Related]

  • 11. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF, Cheng CP, Huang CF, Yen JY, Ko CH, Chen CS.
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [Abstract] [Full Text] [Related]

  • 12. One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study.
    Bachmann S, Bottmer C, Schroder J.
    Psychopathology; 2008 Jul; 41(2):115-23. PubMed ID: 18059113
    [Abstract] [Full Text] [Related]

  • 13. Influence of novel and conventional antipsychotic medication on subjective quality of life.
    Tempier R, Pawliuk N.
    J Psychiatry Neurosci; 2001 Mar; 26(2):131-6. PubMed ID: 11291530
    [Abstract] [Full Text] [Related]

  • 14. [Factors connected with the effect of risperidone on psychopathological symptoms and working memory in schizophrenia].
    Borkowska A, Rybakowski J.
    Psychiatr Pol; 2002 Mar; 36(6 Suppl):225-33. PubMed ID: 12647443
    [Abstract] [Full Text] [Related]

  • 15. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.
    Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Bogetto F.
    Compr Psychiatry; 2008 Mar; 49(2):170-6. PubMed ID: 18243890
    [Abstract] [Full Text] [Related]

  • 16. Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples.
    Nuechterlein KH, Miklowitz DJ, Ventura J, Gitlin MJ, Stoddard M, Lukoff D.
    Psychiatry Res; 2006 Nov 15; 144(2-3):153-66. PubMed ID: 17011635
    [Abstract] [Full Text] [Related]

  • 17. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.
    Hum Psychopharmacol; 2009 Oct 15; 24(7):565-73. PubMed ID: 19790174
    [Abstract] [Full Text] [Related]

  • 18. Nicotine use and its correlates in patients with psychosis.
    Levander S, Eberhard J, Lindström E.
    Acta Psychiatr Scand Suppl; 2007 Oct 15; (435):27-32. PubMed ID: 17953523
    [Abstract] [Full Text] [Related]

  • 19. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome.
    Lindström E, Eberhard J, Levander S.
    Acta Psychiatr Scand Suppl; 2007 Oct 15; (435):5-16. PubMed ID: 17953521
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.